BioSpace News Archive

Terns Pharmaceuticals, Inc. announced that it has granted as of September 1, 2023 equity inducement awards to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in upcoming September Investor Conferences.

PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company) today announced that Dr. Frank Bedu-Addo, Chief Executive Officer of PDS Biotech, will participate and present an overview of the company and its programs at the H.C. Wainwright 25th Annual Global Investment Conference.

IRADIMED CORPORATION announced that the Company will be participating in two upcoming investor conferences.

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference.

Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, confirmed today that it completed an End-of-Phase/Pre-Phase 3 meeting with FDA on its plans to initiate a Phase 3 registrational clinical trial of soquelitinib (formerly CPI-818), the Company’s ITK inhibitor product candidate, in relapsed peripheral T cell lymphoma (PTCL).

PepGen Inc. announced it has received a No Objection Letter from Health Canada for its Clinical Trial Application to initiate the FREEDOM-DM1 Phase 1 study of PGN-EDODM1 in patients with myotonic dystrophy type 1.

Align Technology, Inc. announced the opening of its customer education and training center in Toronto, Canada to promote professional engagement and training about Invisalign clear aligners, iTero scanners and the Align Digital Platform™ for Align customers.

Align Technology, Inc. introduced a new SmartForce feature, attachment-free aligner activation, that helps minimize the number of attachments while maintaining predictable treatment outcomes.

Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a pioneer in expanding consumer access to medication through over the counter (OTC) pathways, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference.